Aldeyra Therapeutics
ALDX
7 hedge funds and large institutions have $5.16M invested in Aldeyra Therapeutics in 2014 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
8% less capital invested
Capital invested by funds: $5.64M → $5.16M (-$478K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$110K |
| 2 |
U
UBS
Zurich,
Switzerland
|
+$4.48K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$1.77K |
| 4 |
Citigroup
New York
|
+$204 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EEG
E.E. Geduld
|
-$105K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.78K |
| 3 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Fidelity Investments
Boston,
Massachusetts
| $5.02M | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $135K | +$110K | +22,558 | New |
|
|
U
3
UBS
Zurich,
Switzerland
| $5K | +$4.48K | +921 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2K | -$1.78K | -365 | -47% |
|
|
BIM
5
BlackRock Investment Management
Wilmington,
Delaware
| $2K | – | – | – |
|
|
6
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2 | +$1.77K | +364 | New |
|
|
EEG
7
E.E. Geduld
| – | -$105K | -16,000 | Closed |
|
|
GSC
8
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$1K | -188 | Closed |
|
|
9
Citigroup
New York
| – | +$204 | +42 | New |
|
ALDX Hedge Fund Activity: Q3 2014 in Review
7 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2014, worth a combined $5.16M — down 8.5% from $5.64M a quarter earlier.
Fund positioning in ALDX was balanced in Q3 2014: 4 funds opened new positions, 4 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $110K. The largest seller was E.E. Geduld, exiting entirely with an estimated $105K sold.
- 7 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $5.16M of Aldeyra Therapeutics stock for Q3 2014, down 8.5% quarter-over-quarter.
- 4 funds opened new Aldeyra Therapeutics positions in Q3 2014 and 4 closed out, a net change of 0 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2014 was Geode Capital Management, an estimated $110K added.
- The largest Aldeyra Therapeutics seller in Q3 2014 was E.E. Geduld, an estimated $105K sold.
Based on aggregated 13F filings for Q3 2014.